Urogen Pharma Ltd
URGN20.820USD
+0.200+0.97%
收盘 11/03, 16:00（美东）报价延迟15分钟
961.87M总市值
亏损市盈率 TTM
关于 Urogen Pharma Ltd 公司
UroGen Pharma Ltd. 是一家位于以色列的生物制药公司。该公司致力于为癌症和泌尿系统疾病提供解决方案。UroGen 开发了 RTGelTM 逆向热凝胶，这是一种专有的缓释水凝胶平台技术，有可能改善现有药物的治疗效果。其主要候选产品包括 MitoGel 和 VesiGel，采用其专有的逆向热触发水凝胶或 RTGel 技术配制而成。MiroGel (UGN-101) 是化疗药物丝裂霉素 C 的缓释制剂，用于治疗低级别上尿路上皮癌，这是一种上尿路上皮癌。VesiGel (UGN-102) 是高剂量丝裂霉素 C 的缓释制剂，用于治疗低级别非肌层浸润性膀胱癌 (LG-NMIBC)。
Urogen Pharma Ltd简介
公司代码URGN
公司名称Urogen Pharma Ltd
上市日期May 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
员工数量235
证券类型Ordinary Share
年结日May 04
公司地址9 Ha'ta'asiya St
城市RA'ANANA
上市交易所NASDAQ Global Market Consolidated
国家Israel
邮编4365007
电话97297707601
网址https://www.urogen.com/
公司代码URGN
上市日期May 04, 2017
CEOMs. Elizabeth A. (Liz) Barrett
Urogen Pharma Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
43.30K
+4.37%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
2.28K
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
业务USD
名称
营收
占比
Jelmyto
24.21M
0.00%
暂无数据
业务
地区
业务USD
名称
营收
占比
Jelmyto
24.21M
0.00%
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
其他
68.76%
持股股东
持股股东
占比
RTW Investments L.P.
9.82%
TD Securities, Inc.
6.90%
Paradigm BioCapital Advisors LP
5.04%
Jefferies LLC
4.75%
Soleus Capital Management, L.P.
4.72%
其他
68.76%
股东类型
持股股东
占比
Hedge Fund
29.41%
Research Firm
21.32%
Investment Advisor/Hedge Fund
20.22%
Investment Advisor
17.19%
Corporation
4.77%
Insurance Company
4.19%
Venture Capital
3.21%
Private Equity
2.11%
Individual Investor
2.10%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
309
45.30M
97.92%
-6.91M
2025Q2
285
53.00M
114.72%
+5.27M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
2023Q2
222
19.52M
83.40%
-392.05K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RTW Investments L.P.
4.54M
9.82%
+709.10K
+18.49%
Jun 30, 2025
TD Securities, Inc.
3.19M
6.9%
+1.44M
+82.40%
Jun 30, 2025
Paradigm BioCapital Advisors LP
2.33M
5.04%
+2.33M
--
Aug 05, 2025
Jefferies LLC
2.20M
4.75%
+1.38M
+169.90%
Jun 30, 2025
Soleus Capital Management, L.P.
2.19M
4.72%
+2.19M
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.11M
4.56%
-34.56K
-1.61%
Jun 30, 2025
SilverArc Capital Management, LLC
2.02M
4.37%
+641.32K
+46.43%
Jun 30, 2025
Pontifax Venture Capital
1.49M
3.21%
-1.00
-0.00%
Mar 14, 2024
Morgan Stanley & Co. LLC
1.47M
3.19%
+1.27M
+633.13%
Jun 30, 2025
Arkin Communication, Ltd.
1.37M
2.96%
--
--
Feb 22, 2024
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
ARK Israel Innovative Technology ETF
2.13%
Tema Oncology ETF
1.43%
ALPS Medical Breakthroughs ETF
0.55%
Hypatia Women CEO ETF
0.19%
iShares Micro-Cap ETF
0.16%
Vanguard US Momentum Factor ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
iShares Biotechnology ETF
0.07%
Fidelity Enhanced Small Cap ETF
0.05%
查看更多
ARK Israel Innovative Technology ETF
占比2.13%
Tema Oncology ETF
占比1.43%
ALPS Medical Breakthroughs ETF
占比0.55%
Hypatia Women CEO ETF
占比0.19%
iShares Micro-Cap ETF
占比0.16%
Vanguard US Momentum Factor ETF
占比0.11%
ProShares Ultra Nasdaq Biotechnology
占比0.1%
Invesco Nasdaq Biotechnology ETF
占比0.1%
iShares Biotechnology ETF
占比0.07%
Fidelity Enhanced Small Cap ETF
占比0.05%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
